Blocking inflammation in the brain: New therapeutic target for the treatment of amyotrophic lateral sclerosis

July 1, 2010
Section of a spinal cord of a mouse. In brown are microglia, the cells that sense SOD1 and produce IL-1ß. Image: MPI for Infection Biology/Meißner/Molawi/Zychlinsky

(PhysOrg.com) -- Amyotrophic lateral sclerosis (ALS) is a common and fatal motor neuron disease. It generates gradual and irreversible damage in the neurons that control movement. The cause of the disease is largely unknown; however, it appears to depend on both inherited and environmental factors. Inflammatory processes in the brain may also cause the death of neurons.

Scientists at the Max Planck Institute for Infection Biology in Berlin have now identified a signalling molecule that may be implicated in the of ALS. Blocking this substance enhances motor performance and increases the life span in mice that have a disease similar to ALS. The results suggest that using this blocking agent to therapeutically intervene could have similar effects in ALS patients. (PNAS, online publication, June 28, 2010)

The research team working with Arturo Zychlinsky at the Max Planck Institute for Infection Biology is mainly interested in how inflammation begins in infectious diseases. They discovered that the enzyme superoxide dismutase 1 (SOD1) regulates inflammation by controlling the activity of another enzyme, caspase-1. This enzyme, in turn, splits the protein Interleukin-1 (IL-1ß) to activate it. The inflammation process begins.

Curiously, it is known that mutations in SOD1 cause a hereditary form of ALS. Moreover, ALS patients have an inflammation and show elevated levels of activated caspase-1. "Caspase-1 probably plays a similar role in ALS as it does in ," says Arturo Zychlinsky.

In the course of further tests, the scientists were able to prove that in ALS misfolded SOD1 enzymes accumulate inside the neurons. This is a danger signal to which the cell reacts by activating caspase-1, which in turn, cleaves Interleukin-1ß and triggers inflammation (fig. 1). This gradually destroys the . When mice carrying mutant SOD1 were treated with a protein that blocks Interleukin-1ß the inflammatory reaction was not only attenuated, the symptoms were also reduced and the animals’ life span prolonged. Together with the ALS clinic at the Charité University Hospital in Berlin, the Max Planck group is now designing a clinical trial to test whether treating ALS patients with Interleukin-1 antagonist is feasible.

More information: Meissner F, Molawi K, Zychlinsky A, Mutant superoxide dismutase 1-induced IL-1β accelerates ALS pathogenesis. PNAS 2010, June 28, 2010

Related Stories

Recommended for you

Cinnamon turns up the heat on fat cells

November 21, 2017
New research from the University of Michigan Life Sciences Institute has determined how a common holiday spice—cinnamon—might be enlisted in the fight against obesity.

How rogue immune cells cross the blood-brain barrier to cause multiple sclerosis

November 21, 2017
Drug designers working on therapeutics against multiple sclerosis should focus on blocking two distinct ways rogue immune cells attack healthy neurons, according to a new study in the journal Cell Reports.

New simple test could help cystic fibrosis patients find best treatment

November 21, 2017
Several cutting-edge treatments have become available in recent years to correct the debilitating chronic lung congestion associated with cystic fibrosis. While the new drugs are life-changing for some patients, they do not ...

Researchers discover key signaling protein for muscle growth

November 20, 2017
Researchers at the University of Louisville have discovered the importance of a well-known protein, myeloid differentiation primary response gene 88 (MyD88), in the development and regeneration of muscles. Ashok Kumar, Ph.D., ...

New breast cell types discovered by multidisciplinary research team

November 20, 2017
A joint effort by breast cancer researchers and bioinformaticians has provided new insights into the molecular changes that drive breast development.

Brain cell advance brings hope for Creutzfeldt-Jakob disease

November 20, 2017
Scientists have developed a new system to study Creutzfeldt-Jakob disease in the laboratory, paving the way for research to find treatments for the fatal brain disorder.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.